Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

• Status: Recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital

Criteria

Inclusion Criteria:

1. high risk Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma with the indications for allogeneic transplantation;

2. Have haploidentical donors

3. All patients should aged 12 to 65 years;

4. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;

5. Renal function: creatinine ≤the upper limit of normal;

6. Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;

7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;

8. Have signed informed consent.

Exclusion Criteria:

1. pregnant women;

2. Patients with mental illness or other states unable to comply with the protocol;